Stone X Group Inc. Novartis Ag Transaction History

Stone X Group Inc.

$2.06 Trillion
Q2 2025

A detailed history of Stone X Group Inc. transactions in Novartis Ag stock. As of the latest transaction made, Stone X Group Inc. holds 2,224 shares of NVS stock, worth $290,832. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,224

Previous 4,085 45.56%

Holding current value

$290,832

Previous $466 Million 42.29%

% of portfolio

0.01%

Previous 0.19%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$101.96 - $121.01 $189,747 - $225,199	-1,861 Reduced 45.56%	2,224 $269 Million
Q1 2025 Aug 13, 2025	BUY	$97.14 - $115.57 $179,029 - $212,995	1,843 Added 82.2%	4,085 $466 Million
Q4 2024 Aug 13, 2025	BUY	$96.78 - $117.18 $216,980 - $262,717	2,242 New	2,242 $218 Million
Q4 2023 Aug 13, 2025	BUY	$92.27 - $101.54 $201,886 - $222,169	2,188 New	2,188 $221 Million
Q3 2023 Aug 13, 2025	SELL	$94.73 - $105.13 $33,060 - $36,690	-349 Reduced 13.25%	2,285 $233 Million
Q2 2023 Aug 13, 2025	BUY	$92.52 - $104.91 $243,697 - $276,332	2,634 New	2,634 $266 Million
Q1 2023 Aug 13, 2025	BUY	$80.03 - $92.81 $189,190 - $219,402	2,364 New	2,364 $217 Million
Q2 2022 Aug 13, 2025	SELL	$80.52 - $93.75 $323,046 - $376,125	-4,012 Reduced 53.85%	3,439 $291 Million
Q1 2022 Aug 13, 2025	BUY	$80.11 - $90.62 $596,899 - $675,209	7,451 New	7,451 $654 Million
Q4 2021 Feb 10, 2022	SELL	$79.7 - $88.13 $8.38 Million - $9.27 Million	-105,169 Closed	0 $0
Q3 2021 Oct 20, 2021	BUY	$81.78 - $95.14 $8.6 Million - $10 Million	105,169 New	105,169 $8.6 Million
Q3 2017 Nov 13, 2017	SELL	$74.14 - $77.27 $1.65 Million - $1.72 Million	-22,265 Closed	0 $0
Q2 2017 Aug 31, 2017	BUY	N/A	22,265	22,265 $1.86 Million

Others Institutions Holding NVS

# of Institutions

1,561

Shares Held

136M

Call Options Held

1.72M

Put Options Held

1.7M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $281B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Account